David Arkowitz - Jun 15, 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
Chief Financial Officer
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
Stock symbol
MCRB
Transactions as of
Jun 15, 2022
Transactions value $
$0
Form type
4
Date filed
10/31/2022, 06:05 PM
Previous filing
Feb 8, 2022
Next filing
Jun 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MCRB Common stock Options Exercise $0 +5K +7.63% $0.00 70.5K Jun 15, 2022 Direct
transaction MCRB Common stock Award $0 +42.5K +60.29% $0.00 113K Oct 27, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MCRB Restricted Stock Units Options Exercise $0 -5K -100% $0.00* 0 Jun 15, 2022 Common Stock 5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 42,500 shares.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3 On June 1, 2021, the reporting person was granted an award of restricted stock units, 100% of which vested and settled on June 15, 2022.